Treatment News : Vancouver Injection Drug Users Moderately Interested in PrEP

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 19, 2014

Vancouver Injection Drug Users Moderately Interested in PrEP

A study of HIV-negative injection drug users (IDUs) in Vancouver, British Columbia, found that about a third expressed willingness to take Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) to prevent HIV. Publishing their findings in AIDS Behavior, researchers gave questionnaires to 543 HIV-negative IDUs enrolled in the Vancouver Injection Drug Users Study. The questionnaires, which asked about knowledge of and interest in PrEP, were administered between December 2012 and May 2013.

Sixteen (3 percent) of the participants already knew about PrEP. After being informed about Truvada, 192 (35.4 percent) said they were willing to take the daily oral medication if it were made available to Canadians. (The drug, which is also used to treat HIV in combination with other antiretrovirals, is currently only approved as PrEP in the United States.)

After adjusting for various factors, the researchers found that younger age was associated with a 30 percent greater likelihood of interest in PrEP for every relative decade of youth. In addition, those who were not regularly employed were 67 percent more likely to use PrEP than those who had a regular job; those engaging in sex work were 2.29 times as likely to use PrEP than those who did not engage in sex work; and those who reported more than one sex partner in the past six months were twice as likely to express interest in PrEP as those who reported no sex partners.

Out of the 192 participants who expressed interest in taking PrEP, 115 (21.2 percent) said they were still willing to do so after being informed of Truvada’s potential side effects, which nurses described to them as including nausea, abdominal pain, headache, weight loss and, rarely, kidney failure or bone toxicity. When told that PrEP might not have 100 percent efficacy, 136 (25 percent) of the participants were still willing to take PrEP.

To read the study abstract, click here.

Search: Injection drug users, PrEP, pre-exposure prophylaxis, Truvada, tenofovir, emtricitabine, AIDS Behavior, Vancouver Injection Drug Users Study.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.